Berardis Domenico De, Rapini Gabriella, Olivieri Luigi, Giardini Agostina, Lauretis Ida De, Serroni Nicola, Orsolini Laura, Fornaro Michele, Iasevoli Felice, Trotta Sabatino, Cottura Paolo, Vellante Federica, Alessandrini Marco, Giannantonio Massimo Di
National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini," Teramo, Italy.
Department of Neurosciences and Imaging, Chair of Psychiatry, University "G. d'Annunzio," Chieti, Italy.
Clin Psychopharmacol Neurosci. 2021 Feb 28;19(1):174-178. doi: 10.9758/cpn.2021.19.1.174.
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D/D receptors with preferential binding to the D receptor, antagonism of 5HT receptors, and partial agonism of 5HT. Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.
卡立哌嗪是一种新型抗精神病药物，它对多巴胺D2/D3受体具有部分激动作用，对D3受体具有优先结合力，对5-HT2A受体具有拮抗作用，对5-HT1A受体具有部分激动作用。目前，卡立哌嗪已在精神分裂症患者、双相情感障碍患者中显示出临床疗效，以及在重度抑郁症（MDD）患者和难治性MDD患者中的辅助治疗效果。在本病例系列中，我们报告了两名难治性精神分裂症患者，他们对氯氮平有部分反应，联合使用卡立哌嗪后获益。卡立哌嗪联合使用在改善氯氮平的不良代谢效应方面也有显著效果。
